X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company, engaged in the discovery and development of therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases. Co.'s pipeline is comprised of oral, small molecule antagonists of chemokine receptor CXCR4, which is designed to treat a range of rare diseases, including primary immunodeficiencies, and certain types of cancer. Co.'s primary product candidate, mavorixafor, is an oral, allosteric antagonist of the CXCR4 receptor designed to correct the abnormal signaling caused by the receptor/ligand interaction and enable mobilization and trafficking of immune cells. The XFOR stock yearly return is shown above.
The yearly return on the XFOR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XFOR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|